2024年9月,美国临床肿瘤学会(ASCO)的官方期刊Journal of Clinical Oncology发表了题为“Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted T...
they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data
RIGHT Choice是首个针对侵袭性HR+/HER2-转移性乳腺癌包括内脏危象患者的随机II期临床研究,纳入了222例既往未接受过系统性治疗的绝经前/围绝经期HR+/HER2-、疾病更具侵袭性特点(包括有症状的内脏转移、快速进展、症状性非内脏疾病)的晚期乳腺癌女性患者,按1:1的比例随机分配至瑞波西利联合内分泌治疗和戈舍瑞林组或...
根据ER、PR、HER2、Ki-67四个指标的表达程度划分的病理分型(Luminal A型、Luminal B型、HER2、三阴性)就是乳腺癌瘤间异质性的典型体现[19]。 病理视角:HER2异质性的认知 自2007年起,ASCO/CAP对HER2检测给出推荐意见,包括:病理检测...
DESTINY-Breast06研究新突破,拓展抗HER2治疗获益人群。 美国临床肿瘤学会(ASCO)年会于2024年5月31日至6月4日在美国芝加哥盛大召开,本次大会公布了多项乳腺癌领域的最新成果,其中德曲妥珠单抗(T-DXd)作为HER2靶向的代表性ADC药物更是讨论的热点。T-DXd是首个在HER2低表达乳腺癌领域开展III期临床试验并取得阳性结果的...
[16] Bardia, Aditya et al. “Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.”Journal of clinical oncology : official journal of the American Society of Clinical Oncologyvol. 42,19 (2024): ...
美国真实世界研究揭示HR低阳性、HR中/高阳性、HR阴性HER2阳性MBC的不同特征。在HER2阳性转移性乳腺癌（MBC）患者中，HR阳性与HR阴性肿瘤患者的治疗模式和临床结局存在差异。根据ASCO/CAP指南[1]，区分HR阳性和HR阴性肿瘤的免疫组织化学检测的现有标准阈值为≥1%，HR低阳性（1%-9%肿瘤细胞HR染色阳性）乳腺癌与传统的...
[3]、Cristofanilli, Massimo et al. “Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 random...
* 第二类是第二型人类上皮生长因子受体阳性(HER2+),使用针对HER2蛋白而设的标靶药可收理想的效果; * 第三类是荷尔蒙受体和HER2受体均呈阴性(HR-/HER2-),故称为三阴性乳癌(triple negative breast cancer),主要的药物治疗方案为化疗; * 第四类是荷尔蒙受体和HER2受体均呈阳性(HR+/HER2+),我们称之为HR+ HER2...
4.Finn RS, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16...